Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) (AMA-VACC)
An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod)
Sponsor: Novartis Pharmaceuticals
A PHASE4 clinical study on Secondary Progressive Multiple Sclerosis, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 12 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jun 2024 [monthly]
Completed PHASE4
▶ Show 7 earlier versions
-
Sep 2022 — Jan 2023 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Feb 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE4
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE4
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .